🔍

SENORES - Senores Pharma.

📊 NSE: SENORES 🏢 Pharmaceuticals - Indian - Formulations 📅 Last Updated: 12/14/2025 13:00

📢 Recent Corporate Announcements

Senores Pharmaceuticals to Host Group Analyst Meet on March 12, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 09 Mar 2026, 04:35 PM

Senores Pharmaceuticals Limited has scheduled a group meeting with analysts and institutional investors on March 12, 2026, at 11:00 AM IST. The meeting will be held physically at the company's corporate office in Ahmedabad, Gujarat. Management intends to discuss publicly available information and has clarified that no unpublished price sensitive information (UPSI) will be shared. This routine interaction is part of the company's investor relations engagement following its listing.

Group meeting with Analysts and Institutional Investors scheduled for March 12, 2026
Interaction to commence at 11:00 AM IST at the Ahmedabad corporate office
Discussions will be based strictly on publicly available information with no UPSI disclosure
Official intimation filed on March 09, 2026, under SEBI LODR Regulation 30(6)

💡 Investors should watch for any post-meeting presentations or transcripts uploaded to the exchange for insights into management's commentary on business growth. No immediate trading action is required as this is a routine disclosure.

Senores Pharma Issues $4.1 Million Corporate Guarantee for US Subsidiary

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 03 Mar 2026, 03:06 PM

Senores Pharmaceuticals Limited has provided a corporate guarantee of up to USD 4,100,000 (approximately INR 34-35 crores) to HDFC Bank. This guarantee supports credit facilities for its wholly-owned US subsidiary, Senores Pharmaceuticals Inc. The agreement has a maximum tenure of 10 years and is conducted at arm's length. While this creates a contingent liability for the parent company, it facilitates capital access for its international operations.

Corporate guarantee issued for an amount up to USD 4,100,000
Guarantee provided to HDFC Bank for credit facilities of US-based wholly-owned subsidiary
Maximum tenure of the credit facilities and associated guarantee is 10 years
Transaction will be reflected as a contingent liability in the company's financial statements
Promoter interest is limited to directorships in the subsidiary, maintaining arm's length status

💡 Investors should monitor the growth and debt-servicing capability of the US subsidiary to ensure the guarantee is not invoked. No immediate action is required as this is a standard financial support structure for global subsidiaries.

Senores Pharma Issues $1.5M Corporate Guarantee for US Subsidiary Havix Group

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 03 Mar 2026, 03:00 PM

Senores Pharmaceuticals has issued a corporate guarantee worth USD 1.5 million to HDFC Bank to secure additional credit facilities for its US-based material subsidiary, Havix Group Inc. (Aavis Pharmaceuticals). This guarantee is an extension of a previous arrangement from July 2025 and will remain valid for up to 10 years or until the credit facility is closed. While this adds to the parent company's contingent liabilities, it provides necessary financial support for the subsidiary's operations. The transaction is conducted at arm's length with no direct promoter interest beyond directorships.

Corporate guarantee issued for USD 1,500,000 to HDFC Bank Limited.
Beneficiary is Havix Group Inc. (Aavis Pharmaceuticals), a material subsidiary in the USA.
The maximum tenure for the credit facilities and the guarantee is 10 years.
The guarantee will be recorded as a contingent liability in the company's financial statements.
This is a follow-up to a previous credit facility intimation dated July 10, 2025.

💡 Investors should note the increase in contingent liabilities but recognize this as standard financial support for a material subsidiary. Monitor the subsidiary's operational performance to ensure it can service the debt independently.

Senores Pharmaceuticals to Host Group Investor Meeting on March 06, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 02 Mar 2026, 03:26 PM

Senores Pharmaceuticals Limited has scheduled a physical group meeting with analysts and institutional investors on March 06, 2026. The meeting is set to commence at 03:30 P.M. IST at the company's corporate office in Ahmedabad, Gujarat. Management has explicitly stated that discussions will be limited to publicly available information and no unpublished price sensitive information (UPSI) will be shared. This routine disclosure follows Regulation 30(6) of the SEBI Listing Obligations and Disclosure Requirements.

Group meeting with analysts and institutional investors scheduled for March 06, 2026.
The meeting will be held physically at the Ahmedabad corporate office starting at 03:30 P.M. IST.
Discussions will be strictly based on publicly available information to ensure compliance.
The schedule is subject to change based on exigencies from either the host or the company.

💡 Investors should watch for any investor presentations or meeting transcripts filed with the exchanges following the event for insights into management's outlook. No immediate trading action is required based on this routine scheduling notice.

Senores Pharmaceuticals Schedules Group Analyst and Investor Meet for March 06, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 02 Mar 2026, 03:21 PM

Senores Pharmaceuticals Limited has announced a group meeting with analysts and institutional investors scheduled for March 06, 2026. The meeting will be held physically at the company's corporate office in Ahmedabad, Gujarat, starting at 03:30 P.M. IST. The company clarified that discussions will be based strictly on publicly available information, ensuring no unpublished price sensitive information is shared. This is a standard regulatory disclosure under SEBI (LODR) Regulations to maintain transparency with the investment community.

Group meeting with analysts and institutional investors scheduled for March 06, 2026
The meeting will commence at 03:30 P.M. IST at the Ahmedabad corporate office
Discussions will be limited to publicly available information with no UPSI shared
Disclosure made in compliance with Regulation 30(6) of SEBI (LODR) Regulations, 2015

💡 No immediate action is required as this is a routine investor engagement. Investors may look for any subsequent investor presentations or transcripts for potential insights into the company's outlook.

Senores Pharma Clarifies Use of Funds from 11.7 Lakh Warrant Issue for Subsidiary Working Capital

🟡 NEUTRAL ⭐ 6/10

FUNDRAISE 📅 13 Feb 2026, 05:54 PM

Senores Pharmaceuticals has issued a clarification regarding its proposed preferential issue of 1,170,000 convertible equity warrants. The company specified that a portion of the funds raised will be utilized to provide loans to its 75%-owned subsidiary, Apnar Pharma Private Limited, to meet its working capital requirements. This follows the company's acquisition of the majority stake in Apnar Pharma in December 2025. The disclosure provides transparency on capital allocation following the upcoming Extra-Ordinary General Meeting.

Proposed issue and allotment of 11,70,000 convertible equity warrants via preferential issue.
Funds earmarked for granting loans to subsidiary Apnar Pharma Private Limited for working capital.
Company confirms 75% ownership of Apnar Pharma following an acquisition in December 2025.
Clarification issued as an amendment to the EGM notice dated January 07, 2026.

💡 Investors should monitor the successful completion of the warrant issue and the subsequent impact of the working capital infusion on Apnar Pharma's operational performance.

Senores Pharma Clarifies Preferential Issue of 11.7 Lakh Warrants at ₹812 Per Share

🟡 NEUTRAL ⭐ 7/10

FUNDRAISE 📅 04 Feb 2026, 03:25 PM

Senores Pharmaceuticals has issued a clarification regarding its upcoming preferential issue of 11,70,000 convertible equity warrants. The company has fixed the fair value for the conversion of these warrants at ₹812.00 per share, based on a valuation report by Maitri Valuation Private Limited. Although the issue is less than 5% of the post-issue capital, the company provided these details to comply with its Articles of Association. The valuation methodology assigned 100% weightage to the Market Approach as it yielded the highest floor price compared to Asset and Income approaches.

Proposed issue and allotment of 11,70,000 convertible equity warrants on a preferential basis.
Fair value for conversion of warrants determined at ₹812.00 per share.
Valuation methodology assigned 100% weightage to the Market Price Method.
The quantum of the proposed issue is less than 5% of the post-issue fully diluted share capital.
Independent valuation conducted by Maitri Valuation Private Limited as per company Articles of Association.

💡 Investors should monitor the upcoming Extra-Ordinary General Meeting results for formal approval of this fundraise. The pricing at ₹812 provides a benchmark for the company's internal valuation of its equity.

Senores Pharma Shareholders Approve 11.7 Lakh Convertible Warrants Issue to Promoters

🟢 POSITIVE ⭐ 7/10

FUNDRAISE 📅 31 Jan 2026, 04:22 PM

Senores Pharmaceuticals Limited has received shareholder approval for the issuance of 11,70,000 convertible equity warrants to the promoter group on a preferential basis. The special resolution was passed with a significant majority of 96.45% during the EGM held on January 31, 2026. Notably, while the resolution passed, 25.21% of institutional votes were cast against the proposal. This issuance represents a strategic capital infusion by the promoters, signaling long-term commitment to the company's growth.

Approved issuance of 11,70,000 convertible equity warrants to the Promoter and Promoter Group.
The special resolution was passed with 96.455% votes in favor and 3.545% against.
Public Institutions cast 6,42,044 votes (25.21% of their polled votes) against the resolution.
A total of 1,81,11,053 votes were polled during the EGM process.

💡 The promoter's decision to infuse capital via warrants is a positive signal of confidence; however, investors should monitor the specific pricing and use of proceeds. Keep an eye on the eventual conversion of these warrants into equity and its impact on EPS dilution.

Senores Pharma EGM Approves 11.70 Lakh Convertible Warrants to Promoters

🟢 POSITIVE ⭐ 7/10

FUNDRAISE 📅 31 Jan 2026, 03:23 PM

Senores Pharmaceuticals Limited held an Extra-Ordinary General Meeting (EGM) on January 31, 2026, to approve a significant fundraise. The company sought shareholder approval for the issuance of 11,70,000 convertible equity warrants on a preferential basis. These warrants are being issued specifically to the Promoter and Promoter Group category, indicating a capital infusion from the company's leadership. The resolution was presented as a special resolution, and the final voting results are expected to be submitted shortly.

Issuance of 11,70,000 convertible equity warrants approved via special resolution
Fundraise conducted through a preferential issue on a private placement basis
Warrants exclusively allocated to the Promoter and Promoter Group category
EGM held via Video Conferencing with 48 members in attendance
Remote e-voting was conducted between January 28 and January 30, 2026

💡 Investors should view the promoter-led capital infusion as a sign of confidence in the company's long-term growth. Monitor the official disclosure of the warrant conversion price to evaluate the potential equity dilution.

Senores Pharma Q3FY26 PAT Surges 85% YoY; ANDA Portfolio Quadruples to 46

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 27 Jan 2026, 06:17 PM

Senores Pharmaceuticals reported a robust Q3FY26 with consolidated revenue growing 64% YoY to ₹175 crores and PAT increasing 85% to ₹32 crores. The company's ANDA portfolio has expanded significantly from 12 to 46 approved products within a year, providing a strong pipeline for future launches. Management maintained its FY26 guidance of 50% revenue growth and 100% PAT growth, supported by the recent acquisition of Apnar Pharma. The India branded generics business also showed explosive growth, increasing six-fold during the quarter.

Consolidated EBITDA grew 86% YoY to ₹54 crores with margins expanding 360 bps to 30.9%
ANDA portfolio quadrupled to 46 approved products, with 28 approved ANDAs currently available for launch
Completed 75% acquisition of Apnar Pharma, targeting ₹120-150 crores revenue from this unit in FY27
India branded generics revenue grew 6x YoY to ₹10.5 crores in Q3FY26
9MFY26 PAT more than doubled YoY to ₹84 crores, tracking ahead of annual guidance

💡 Investors should view the strong execution and margin expansion positively, especially the rapid scaling of the ANDA portfolio and the strategic US acquisition. Monitor the integration of Apnar Pharma and the rollout of the 28 approved-but-unlaunched ANDAs as key growth drivers.

Senores Pharmaceuticals Releases Q3 & 9M FY26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 20 Jan 2026, 07:02 PM

Senores Pharmaceuticals Limited has officially released the audio recording of its earnings conference call for the quarter and nine months ended December 31, 2025. The call, conducted on January 20, 2026, featured participation from the Chairman, Managing Director, and CFO. This disclosure is a standard regulatory requirement under SEBI LODR Regulations to ensure all investors have access to management discussions. The recording is available on the company's website for public review.

Earnings conference call for Q3 and 9M FY26 was held on January 20, 2026.
Audio recording is now accessible via the company's investor relations weblink.
Top leadership including Chairman Sanjay Majmudar and MD Swapnil Shah represented the company.
The company confirmed that no Unpublished Price Sensitive Information (UPSI) was shared during the call.

💡 Investors should listen to the audio recording to understand management's perspective on the company's financial health and future outlook. No immediate action is required as this is a routine compliance filing.

Senores Pharmaceuticals Reports Zero Deviation in Utilization of Rs 500 Cr IPO Proceeds

🟡 NEUTRAL ⭐ 6/10

REGULATORY 📅 20 Jan 2026, 05:29 PM

Senores Pharmaceuticals has confirmed that there were no deviations in the utilization of the Rs 500 crore raised via its December 2024 IPO for the quarter ended December 31, 2025. As of the reporting date, the company has successfully deployed Rs 362.12 crore towards its stated objectives. Key expenditures include debt repayment of approximately Rs 93.3 crore and working capital funding of nearly Rs 99 crore. The audit committee and monitoring agency, CARE Ratings, have reviewed and validated these findings.

Total IPO proceeds of Rs 500 crore raised on December 26, 2024, with zero deviation reported.
Cumulative utilization of funds stands at Rs 362.12 crore as of December 31, 2025.
Rs 107 crore allocated for Havix facility capex, with Rs 6.98 crore utilized to date.
Debt repayment of Rs 73.10 crore for the company and Rs 20.20 crore for subsidiaries has been completed.
Unutilized amounts of Rs 0.40 crore from debt repayment were redirected to General Corporate Purposes (GCP) as per board approval.

💡 Investors should track the deployment of the remaining Rs 100 crore earmarked for the Havix sterile injection facility, as this is a key growth driver. The completion of debt repayment is a positive step for the company's financial health.

Senores Pharma Q3 FY26 PAT Jumps 105% YoY to ₹33.6 Cr; EBITDA Margins Expand to 30.9%

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 20 Jan 2026, 03:25 PM

Senores Pharmaceuticals reported a robust Q3 FY26 with total income growing 64.1% YoY to ₹174.6 crore. Net profit (PAT) surged 104.7% YoY to ₹33.6 crore, supported by a significant 360 bps expansion in EBITDA margins to 30.9%. The company successfully completed a 75% stake acquisition in Apnar Pharmaceuticals, adding USFDA-approved facilities and 5 ANDAs to its portfolio. Regulated markets remain the primary growth driver, contributing 65% of total revenue with high EBITDA margins of 40%.

Total Income for Q3 FY26 grew 64.1% YoY to ₹174.6 crore; 9M FY26 income reached ₹474.3 crore.
EBITDA increased by 85.9% YoY to ₹54.0 crore in Q3, with margins improving from 27.3% to 30.9%.
Completed 75% acquisition of Apnar Pharma for an Enterprise Value of ~₹91 crore to boost US and UK market access.
Strong product pipeline with 46 approved ANDAs (137 strengths) and 22 additional ANDAs currently under development.
Emerging markets revenue grew 48% YoY in Q3, with EBITDA margins jumping from 1% to 13%.

💡 Investors should monitor the integration of Apnar Pharma and the commercialization of the 102 pending ANDA strengths which provide high revenue visibility. The stock remains attractive due to strong margin expansion and a robust cash flow from operations of ₹51 crore for 9M FY26.

Senores Pharma Q3FY26 PAT Surges 105% YoY to Rs 34 Cr; Revenue up 64%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 20 Jan 2026, 02:16 PM

Senores Pharmaceuticals reported a stellar performance for Q3FY26, with consolidated revenue growing 64% YoY to Rs 175 crore and PAT doubling to Rs 34 crore. The company's regulated markets business remains the primary driver, contributing 64.5% of revenue with a strong 40% EBITDA margin. Significant improvement was seen in the emerging markets segment, where EBITDA margins jumped from 1% to 13% YoY. The integration of Apnar Pharmaceuticals is progressing ahead of schedule, with 75% of the stake already acquired and the remainder expected by Q2FY27.

Consolidated Q3FY26 Revenue grew 64% YoY to Rs 175 crore, while PAT rose 105% to Rs 34 crore.
Regulated market revenue increased 60.5% YoY to Rs 112.7 crore with a robust 40% EBITDA margin.
Emerging markets business saw a massive margin expansion of 1,200 bps, reaching 13% EBITDA margin in Q3.
Strong product pipeline with 46 approved ANDAs and 22 additional ANDAs currently under development.
Operating Cash Flow for 9MFY26 stood at Rs 51 crore, showing significantly improved EBITDA-to-OCF conversion.

💡 Investors should view these results positively given the high growth in both top-line and bottom-line along with significant margin expansion in emerging markets. Monitor the successful launch of the 28 approved-but-unlaunched ANDAs as a key growth catalyst for FY27.

Senores Pharma Q3 FY26 PAT Surges 105% to Rs 34 Cr; Revenue Up 64% YoY

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 20 Jan 2026, 02:08 PM

Senores Pharmaceuticals reported a robust Q3 FY26 with a 64% YoY increase in total income to Rs 175 crore and a 105% surge in PAT to Rs 34 crore. The company's regulated markets segment grew 60.5% YoY with a strong 40% EBITDA margin, while emerging markets saw a significant margin expansion from 1% to 13%. The acquisition of Apnar Pharmaceuticals is progressing well, with 75% stake already acquired and integration happening faster than expected. With 46 approved ANDAs and over 100 strengths yet to be launched, the company maintains a strong growth pipeline.

Q3 FY26 PAT grew 105% YoY to Rs 34 crore, while 9M FY26 PAT rose 110% to Rs 85 crore.
Consolidated EBITDA for Q3 FY26 stood at Rs 54 crore, representing an 86% YoY growth.
Regulated market revenue grew 60.5% YoY to Rs 112.7 crore with a high EBITDA margin of 40%.
Emerging markets EBITDA margin jumped 1,200 bps YoY to 13% in Q3 FY26.
Strong product pipeline with 46 approved ANDAs and 22 more under development.

💡 The stock shows strong operational leverage and margin expansion across geographies. Investors should monitor the launch of the 100+ pending ANDA strengths as a key growth catalyst.

View All SENORES Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Regulated Markets grew 86.9% YoY to INR 106.9 Cr in Q2 FY26; Emerging Markets declined 13.4% YoY to INR 31.7 Cr; Branded Generics grew 1337.3% YoY to INR 11.9 Cr; API segment declined 20.5% YoY to INR 2.9 Cr.

Geographic Revenue Split

Regulated Markets (US, Canada, UK) contributed 69.7% of Q2 FY26 revenue (INR 106.9 Cr); Emerging Markets contributed 20.7% (INR 31.7 Cr); Branded Generics (India) contributed 7.8% (INR 11.9 Cr).

Profitability Margins

Gross Margin improved to 64.7% in Q2 FY26 (up 1,230 bps YoY); EBITDA Margin reached 30.6% (up 750 bps YoY); PAT Margin stood at 18.6% (up 560 bps YoY).

EBITDA Margin

EBITDA Margin was 30.6% in Q2 FY26, a 750 bps increase from 23.1% in Q2 FY25, driven by a higher share of own ANDA product launches which carry 40-42% margins.

Capital Expenditure

Planned Capex of INR 107.0 Cr for a sterile injection manufacturing facility in Atlanta; INR 154.8 Cr allocated for inorganic growth and strategic initiatives.

Credit Rating & Borrowing

Company plans to use INR 73.1 Cr for full/partial repayment of borrowings and INR 20.2 Cr for subsidiary Havix's debt repayment. Specific interest rates not disclosed.

⚙️ Operational Drivers

Raw Materials

Not disclosed in available documents; COGS represented 37.2% of revenue in Q2 FY26 (INR 57.1 Cr).

Key Suppliers

Not disclosed in available documents; management notes dependence on a limited supplier base as a risk.

Capacity Expansion

US facility expanding from 1.2 billion units to 2 billion units; 3rd manufacturing line operational in Q3 FY26 and 4th line by end of FY26.

Raw Material Costs

Total COGS for H1 FY26 was INR 118.4 Cr, representing 39.5% of total income, compared to INR 82.5 Cr in H1 FY25.

Manufacturing Efficiency

Capacity utilization is being optimized through the addition of new manufacturing lines in the US to reach 2 billion units to support a 25%+ growth target.

📈 Strategic Growth

Expected Growth Rate

25%

Growth Strategy

Growth driven by 4 pillars: (i) Expansion of ANDA portfolio in Regulated Markets; (ii) Scale-up of CDMO/CMO segment; (iii) Portfolio expansion in Emerging Markets; and (iv) Scale-up of Branded Generics in India.

Products & Services

Pharmaceutical formulations including Tablets, Capsules, Sterile Injections, and Controlled Substances; also provides CDMO/CMO services and management consultancy.

Brand Portfolio

Senores, Havix, Ratnatris.

New Products/Services

Planned new product launches every quarter for the next 4-5 quarters; 86 new approvals received in Emerging Markets during Q2 FY26.

Market Expansion

Expanding US manufacturing footprint in Atlanta and increasing penetration in Emerging Markets through 86 new product approvals.

Strategic Alliances

Utilizes profit-share models with marketing partners for own ANDA products, supplemented by licensing fees and COGS reimbursement.

🌍 External Factors

Industry Trends

Industry involves a 5-year journey from development to commercialization; shift toward own ANDA launches is driving margin expansion from 35% toward 40-42% in regulated markets.

Competitive Landscape

Competes in the global generic and CDMO markets; management focuses on 'mid-tier standardized markets' to avoid high-competition segments.

Competitive Moat

Moat built on US-based manufacturing for controlled substances, a diversified business model (CDMO + Own Products), and a strong pipeline of 86+ new approvals.

Geopolitical Risks

Geographical concentration risk in the US market; regulatory changes in pharmaceutical standards could trigger litigation or product bans.

⚖️ Regulatory & Governance

Industry Regulations

Compliance with US FDA, Indian Accounting Standards (Ind AS), and Section 133 of the Companies Act, 2013.

Environmental Compliance

Subject to various environmental laws regarding prevention and control of pollution; specific costs not disclosed.

Taxation Policy Impact

Effective tax rate resulted in INR 15.8 Cr tax expense for H1 FY26 on PBT of INR 67.1 Cr (~23.5%).

⚠️ Risk Analysis

Key Uncertainties

Regulatory non-compliance risk could trigger product bans or penalties; 180-day exclusivity periods for generics create revenue cliffs if new products aren't launched.